Hyperinsulinemia and hypofibrinolysis: Effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients

Metabolism: Clinical and Experimental

Volumn 46, Issue 9, 1997, Pages 1074-1079

  Lormeau, B ^a,b   Aurousseau, M H ^a   Valensi, P ^a   Paries, J ^a   Attali, J R ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b HÔPITAL JEAN VERDIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULINEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030874906     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90281-X     Document Type: Article

References (35)

1. Landin K, Tengborn L, Smith U: Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 227:273-278, 1990
2. Speiser W, Speiser P, Minar E, et al: Activation of coagulation and fibrinolysis in patients with arteriosclerosis: Relation to localization of vessel disease and risk factors. Thromb Res 59:77-88, 1990
3. Meade TW, Mellows S, Brozovic M: Haemostatic function and ischaemic heart disease. Principal results of the Northwick Park Heart Study. Lancet 2:533-537, 1986
4. Lormeau B, Debussche X, Dieval J, et al: Fibrinolyse et diabète sucré: un rôle dans les complications dégénératives? Ann Med Interne 144:108-116, 1993
5. Juhan-Vague I, Roui C, Alessi MC, et al: Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin. Thromb Haemost 61:370-373, 1989
6. Garcia Frade LJ, De La Calle H, Torrado MC, et al: Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus. Thromb Res 59:51-59, 1990
7. Auwerx J, Bouillon R, Collen D, et al: Tissue type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8:68-72, 1988
8. Juhan-Vague I, Vague P, Alessi MC, et al: Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diabete Metab 13:331-336, 1987
9. Vague P, Juhan-Vague I, Aillaud MF, et al: Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 2:250-253, 1986
10. Lormeau B, Debussche X, Gross S, et al: Acute hyperinsulinism has no effect on fibrinolysis in lean and obese subjects. Diabetes 40:494, 1991 (suppl 1, abstr)
11. Landin K, Tengborn L, Ghmielewska J, et al: The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost 65:130-133, 1991
12. Potter Van Loon BJ, De Bart ACW, Radder JK, et al: Acute exogenous hyperinsulinaemia does not result in elevation of plasma plasminogen activator inhibitor-1 concentration in man. Fibrinolysis 4:93-94, 1990
13. Grant PJ, Kruithof EKO, Felley CP, et al: Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increase in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 79:513-516, 1990
14. Markkolo HV, Puhakainen I, Yki-Jarvinen H: No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man. Thromb Haemost 67:117-120, 1992
15. Alessi MC, Juhan-Vague I, Kooistra T, et al: Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost 60:491-494, 1988
16. Kooistra T, Bosma P, Tons H, et al: Plasminogen activator inhibitor 1: Biosynthesis and mRNA levels are increased by insulin in cultured human hepatocytes. Thromb Haemost 62:723-728, 1989
17. Scarlett JA, Gray RS, Griffin J, et al: Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care 5:353-363, 1982
18. Valensi P, Moura I, Le Magoarou M, et al: Short term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non insulin dependent overweight patients with poor glycemic control despite maximal oral antidiabetic treatment. Diabetes Metab 23:51-57, 1997
19. Juhan-Vague I, Vague P: Hypofibrinolysis and insulin resistance. Diabete Metab 17:96-100, 1991
20. Glaser B, Leibovich G, Nesher R, et al: Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol (Copenh) 118:365-373, 1988
21. Garvey TW, Olefsky JM, Griffin J, et al: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222-234, 1985
22. Grulet H, Durlach V, Hecart AC, et al: Study of the rate of early glucose disappearance following insulin injection: Insulin sensitivity index. Diabetes Res Clin Pract 20:201-207, 1993
23. Vague P, Juhan-Vague I, Chabert V, et al: Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism 38:913-918, 1989
24. Landin K, Tengborn L, Smith U: Elevated fibrinogen and plasminogen activator inhibitor (AI-inf) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 227:273-278, 1990
25. Barakat HA, Carpenter JW, McLendon VD, et al: Influence of obesity, impaired glucose tolerance, and NIDDM on LDL structure and composition. Possible link between hyperinsulinemia and atherosclerosis. Diabetes 39:1527-1533, 1990
26. Ginsberg HN: Lipoprotein physiology in non diabetic and diabetic states. Relationship to atherogenesis. Arteriosclerosis 10:1067-1073, 1990
27. Stiko-Rahm A, Wiman B, Hamsten A, et al: Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 10:1067-1073, 1990
28. Latron Y, Alessi MC, Anfosso F, et al: Effect of low density lipoprotein on secretion of plasminogen activator inhibitor 1 (PAI-1) by human endothelial cells and hepatoma cells. Fibrinolysis 4:82-83, 1990 (suppl)
29. Hajjar KA, Gavish D, Breslow JL, et al: Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339:303-305, 1989
30. Scelles V, Raccah D, Alessi MC, et al: Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states. Diabete Metab 18:38-42, 1992
31. Loskutoff DJ: Regulation of PAI-1 gene expression. Fibrinolysis 5:197-206, 1991
32. Nagi DK, Hendra TJ, Ryle AJ, et al: The relationship of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 33:532-537, 1990
33. Latron Y, Chautan M, Anfosso F, et al: Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor 1 synthesis by endothelial cells. Arterioscler Thromb 11:1821-1829, 1991
34. Etingin OR, Hajjar DP, Hajjar KA, et al: Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J Biol Chem 226:2459-2465, 1991
35. Dawson S, Hamsten A, Wiman H, et al: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity. Arterioscler Thromb 11:183-190, 1991